Will Latest Dabigatran Data Finally Topple Warfarin?

NEW ORLEANS - Boehringer Ingelheim's dabigatran etexilate had comparable efficacy and significantly lower or comparable bleeding rates to warfarin in patients with acute venous thromboembolism, according to data from the RE-COVER trial reported Dec. 6 at the American Society of Hematology meeting in New Orleans

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet